Roche Holding AG (OTCMKTS:RHHBY) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $60.00.

RHHBY has been the subject of a number of research reports. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Royal Bank Of Canada assumed coverage on Roche in a report on Tuesday, September 8th. They set an “outperform” rating on the stock. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective on the stock in a report on Friday, August 7th. HSBC reiterated a “hold” rating on shares of Roche in a research report on Thursday, September 10th. Finally, Oddo Bhf raised Roche to an “outperform” rating in a research note on Tuesday.

Roche Price Performance

Shares of RHHBY stock opened at $57.14 on Tuesday. Roche has a 1 year low of $40.07 and a 1 year high of $60.85. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $54.86 and its 200-day moving average is $52.85.

Hedge Funds Weigh In On Roche

Large investors have recently made changes to their positions in the company. Opal Capital LLC bought a new stake in Roche during the 1st quarter worth about $4,448,000. S&CO Inc. boosted its stake in shares of Roche by 163.0% in the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after purchasing an additional 87,107 shares during the last quarter. North Star Asset Management Inc. bought a new position in shares of Roche in the 2nd quarter valued at about $1,351,000. Puzo Michael J bought a new position in shares of Roche in the 2nd quarter valued at about $1,229,000. Finally, Woodstock Corp acquired a new stake in shares of Roche during the 3rd quarter worth approximately $245,000.

About Roche

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.